Arvinas, Inc. (NASDAQ:ARVN) Receives $56.92 Consensus Price Target from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $56.92.

ARVN has been the subject of several recent analyst reports. Barclays cut their target price on Arvinas from $60.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. HC Wainwright restated a “buy” rating and set a $87.00 target price on shares of Arvinas in a research note on Thursday, October 31st. Wedbush reiterated an “outperform” rating and issued a $57.00 price target on shares of Arvinas in a research note on Tuesday, July 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. Finally, Oppenheimer dropped their price target on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Arvinas by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 6,299,556 shares of the company’s stock valued at $260,046,000 after buying an additional 1,448,166 shares during the period. Swiss National Bank raised its stake in shares of Arvinas by 27.5% during the 1st quarter. Swiss National Bank now owns 114,100 shares of the company’s stock worth $4,710,000 after acquiring an additional 24,600 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Arvinas by 137.2% during the 2nd quarter. SG Americas Securities LLC now owns 86,096 shares of the company’s stock worth $2,292,000 after acquiring an additional 49,799 shares in the last quarter. Candriam S.C.A. increased its stake in Arvinas by 32.0% during the 2nd quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock valued at $16,250,000 after purchasing an additional 147,904 shares in the last quarter. Finally, Magnetar Financial LLC increased its stake in Arvinas by 112.7% during the 2nd quarter. Magnetar Financial LLC now owns 41,992 shares of the company’s stock valued at $1,118,000 after purchasing an additional 22,245 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Price Performance

Arvinas stock opened at $28.04 on Thursday. The company has a market capitalization of $1.93 billion, a PE ratio of -6.00 and a beta of 1.96. Arvinas has a one year low of $14.64 and a one year high of $53.08. The business has a 50 day simple moving average of $25.80 and a 200 day simple moving average of $27.45.

Arvinas (NASDAQ:ARVN) last released its earnings results on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.20. The firm had revenue of $102.40 million during the quarter, compared to analyst estimates of $60.56 million. The firm’s quarterly revenue was up 196.0% on a year-over-year basis. During the same period last year, the business posted ($1.18) earnings per share. Equities analysts anticipate that Arvinas will post -3.32 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.